ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This Phase I, open label, dose determining study of oral niraparib in combination with
ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent
solid cancer. Dose escalation will follow the mTPI-2/Keyboard design. Eligible patients will
receive therapy until disease progression or unacceptable toxicities are experienced.